论文部分内容阅读
目的探讨拉米夫定与胸腺肽 -α1 联合治疗慢性乙型肝炎的近期疗效和安全性。方法通过对照研究方法 ,选择 60例 HBV DNA与 HBe Ag阳性的慢性乙型肝炎患者 ,按 1∶ 1∶ 2的比例随机分配进入 3个不同的治疗组 [拉米夫定 (LAM)组、胸腺肽 -α1 (Tα1 )组和L AM+ Tα1 组 ] ,6个月为一疗程。结果治疗 2 6周后 L AM+ Tα1 组血清 HBe Ag转阴率 (73 .3 % ,2 2 /3 0 ) ,明显高于 L AM组 (13 .3 % ,2 /15 )和 Tα1 组 (2 6.7% ,4/15 ) ,LAM+ Tα1 组分别与 LAM组、Tα1 组 HBe Ag血清转阴率比较 ,转阴患者血清均未发现 HBV前 C区变异株。治疗后 AL T明显下降 ,肝组织炎症坏死程度明显改善 ,肝纤维化程度降低 ,HBs Ag、HBe Ag的表达明显减少。治疗过程无明显的不良反应。结论胸腺肽 -α1 与拉米夫定联合治疗慢性乙型肝炎 ,不良反应少 ,短期疗效明显优于单一用药组 ,是安全、有效的治疗慢性乙型肝炎的方案
Objective To explore the short-term curative effect and safety of lamivudine combined with thymosin-α1 in the treatment of chronic hepatitis B patients. Methods Sixty patients with chronic hepatitis B who were positive for HBV DNA and HBe Ag were selected and randomly divided into three different treatment groups (lamivudine (LAM) group, thymosin -α1 (Tα1) group and LAM + Tα1 group] for 6 months. Results Serum HBeAg negative rates (73.3%, 2 2/3 0) in LAM + Tα1 group were significantly higher than those in LAM group (13.3%, 2/15) and Tα1 group 6.7%, 4/15). Compared with LAM group and Tα1 group, the negative rate of HBeAg seroconversion in LAM + Tα1 group was not significantly different from that in negative group. ALT decreased significantly after treatment, the degree of inflammatory necrosis in liver tissue was significantly improved, the degree of hepatic fibrosis was decreased, and the expression of HBsAg and HBeAg was significantly reduced. No significant adverse reactions during treatment. Conclusion Thymosin-α1 and lamivudine combined treatment of chronic hepatitis B, adverse reactions, short-term efficacy was significantly better than the single-drug group, is safe and effective treatment of chronic hepatitis B program